{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-014197","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.175378+00:00","generated_at":"2026-06-06T01:28:58.570848+00:00","sec_items":["1.01","2.01","5.06","9.01","5.02","5.01","5.03"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CERO Therapeutics completes business combination with PBAX; raises $9.4M PIPE","bullets":["Business combination closed Feb 14, 2024; PBAX merged with CERo, renamed CERO Therapeutics Holdings.","Issued ~7.58M shares to CERo stockholders; 3.075M earnout shares subject to stock price/regulatory milestones.","PIPE financing raised ~$9.4M via 12,580 Series A preferred shares and warrants; convertible bridge notes exchanged.","Entered $25M equity line of credit with Keystone Capital; shares sold at 90% of VWAP, capped at 19.99%.","Lock-up on ~673,504 shares for 180 days or until $12.50 VWAP for 20 days within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-014197","json":"https://secwatch.observer/filing/0001213900-24-014197.json","markdown":"https://secwatch.observer/filing/0001213900-24-014197.md","text":"https://secwatch.observer/filing/0001213900-24-014197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/ea193687-8k_phoenix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:28:58.570848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f35d07f1c","claim":"Mr. Ehrlich was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1109a25597","claim":"Mr. Atwood was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2d4c09f823","claim":"Mr. Byrnes was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"484b88f297","claim":"Mr. Atwood was appointed as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Atwood was appointed as the Company's Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"75b41fd182","claim":"Robyn Rapaport was elected as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On February 14, 2024, the Board increase the size of the Board to seven directors and filled the vacancies caused thereby by electing each of Lindsey Rolfe and Robyn Rapaport to serve as a director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"76a51fd1c8","claim":"Mr. Carter was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Carter was appointed as the Company's Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"977cda776f","claim":"Mr. Corey was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a65ff4ec1d","claim":"Mr. Corey was appointed as Chief Technical Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Corey was appointed as the Company's Chief Technical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Technical Officer"}],"fact_type":"executive_change"},{"claim_id":"bf2461d5d3","claim":"Ms. LaPorte was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ca76379954","claim":"Ms. Kosacz resigned as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"dcb57ac9e1","claim":"Lindsey Rolfe was elected as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On February 14, 2024, the Board increase the size of the Board to seven directors and filled the vacancies caused thereby by electing each of Lindsey Rolfe and Robyn Rapaport to serve as a director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f88a21bf01","claim":"Ms. Loewy resigned as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"116c8e7507684d239fff0c059a3d589c1354416e","claim":"CERO THERAPEUTICS HOLDINGS, INC.: Adopted amended and restated bylaws in connection with Business Combination (effective 2024-02-14).","evidence_excerpt":"and (ii) adopted amended and restated bylaws (as amended, the “ Bylaws ”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"governance_change"},{"claim_id":"4b39577405a7944b4f4a6da4e85b61ba28a49fdc","claim":"CERO THERAPEUTICS HOLDINGS, INC.: Filed second amended and restated certificate of incorporation in connection with Business Combination (effective 2024-02-14).","evidence_excerpt":"the Company (i) filed a second amended and restated certificate of incorporation with the Secretary of State of the State of Delaware (as amended, the “ Certificate of Incorporation ”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"governance_change"},{"claim_id":"def693284d1d5d359465a4981e3c854a061c58eb","claim":"CERO THERAPEUTICS HOLDINGS, INC.: Company ceased being a shell company as a result of the Business Combination (effective 2024-02-14).","evidence_excerpt":"As a result of the Business Combination, the Company ceased being a shell company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"governance_change"},{"claim_id":"983a34e5b4e7c5ad52d465ca3c4c07e73383c46c","claim":"CERO THERAPEUTICS HOLDINGS, INC. completed an acquisition involving CERo Therapeutics, Inc. (closed 2024-02-14).","evidence_excerpt":"On February 14, 2024 (the “ Closing Date ”), Phoenix Biotech Acquisition Corp., a Delaware corporation (“ PBAX ” and, after the consummation of the Business Combination (as defined below), the “ Company ”), completed the previously announced acquisition of CERo Therapeutics, Inc., a Delaware corporation (“ CERo ”), pursuant to the business combination agreement and plan of reorganization","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"CERo Therapeutics, Inc."},{"label":"Closing","value":"2024-02-14"}],"fact_type":"ma_transaction"},{"claim_id":"dbdb6796a61ed6c27b44b421897c899eabf1e458","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Common Stock Purchase Agreement with Keystone Capital Partners, LLC.","evidence_excerpt":"the Company entered into a common stock purchase agreement (the \" Common Stock Purchase Agreement \") with Keystone Capital Partners, LLC (the \" ELOC Investor \")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}